Legal Firm Investigates Potential Securities Class Action Against GLP-1 Company

Berger Montague, a securities litigation firm, is investigating potential claims on behalf of investors who purchased or acquired securities of Hims & Hers Health, Inc.The investigation follows Novo Nordisk's June 23, 2025, announcement that it had terminated its partnership with Hims & Hers over allegations that Hims & Hers engaged in deceptive marketing and sold unapproved compounded versions of semaglutide, the active ingredient in Wegovy and Ozempic.

Berger Montague is examining whether Hims & Hers and certain officers and directors made materially false or misleading statements or failed to disclose material information related to the nature and regulatory status of its GLP-1 offerings, the associated risks, and the partnership with Novo Nordisk.

No formal charges have been filed. The law firm is encouraging investors who purchased or otherwise acquired securities of Hims & Hers to contact them to discuss potential claims.